An Open-label, Single-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects

Trial Profile

An Open-label, Single-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs E 2027 (Primary) ; Diltiazem
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 06 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017.
    • 23 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top